Drug Trial Radar · NCT02189733
Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.
Last checked: Nov 20, 2026Latest source record: Nov 14, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jul 2014
Primary completion
Sep 2014
Sponsor
- Lead sponsor
- Ablynx, a Sanofi companyIndustry
- Sponsor type
- Industry
- First posted
- Jul 15, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the pharmacokinetic characteristics and demonstrate bioequivalence of a reconstituted new lyophilized formulation of caplacizumab for subcutaneous (s.c.) injection as compared to an equal nominal s.c. dose of the reference liquid formulation of caplacizumab. The secondary objective of the study is to compare the safety and tolerability, and the pharmacodynamic parameters of the new formulation with those of the reference formulation.
Conditions
- Healthy Volunteers
Interventions
CaplacizumabBiological
Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics: concentration of caplacizumab in plasmaTime frame: Day 1 (pre-dose) until Day 7
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Clinical
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.